Get the Stockscreener App
16.20
2.70%
-0.46
Lyell Immunopharma Inc stock is traded at $16.20, with a volume of 16,466.
It is down -2.70% in the last 24 hours and down -8.68% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$16.66
Open:
$16.87
24h Volume:
16,466
Relative Volume:
0.42
Market Cap:
$310.07M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-20.51
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
-5.92%
1M Performance:
-8.68%
6M Performance:
+75.74%
1Y Performance:
-27.63%
1-Day Range:
$15.94
$17.31
1-Week Range:
$15.94
$17.59
52-Week Range:
$7.65
$30.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
16.14 | 320.06M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.68 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.21 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.02 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.25 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.18 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Lyell’s dual-targeting CAR T-cell therapy shows promise in lymphoma - Investing.com
Strategies to average down on Lyell Immunopharma Inc.Buy Signal & Risk Controlled Stock Alerts - newser.com
Is Lyell Immunopharma Inc. stock overvalued by current metricsTrade Analysis Report & Expert Verified Stock Movement Alerts - newser.com
How Lyell Immunopharma Inc. stock performs in weak economyWeekly Profit Recap & Daily Volume Surge Signals - newser.com
Lyell Immunopharma Appoints New Financial Leadership Team - TipRanks
Lyell (Nasdaq: LYEL) to present Phase 1/2 ronde-cel LBCL at ASH; FDA RMAT & Fast Track - Stock Titan
Is Lyell Immunopharma Inc. stock attractive for retirement portfoliosQuarterly Portfolio Review & Expert Curated Trade Setup Alerts - newser.com
Volatility clustering patterns for Lyell Immunopharma Inc.July 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com
Real time social sentiment graph for Lyell Immunopharma Inc.2025 Momentum Check & Stock Portfolio Risk Management - newser.com
Will Lyell Immunopharma Inc. benefit from macro trendsWeekly Risk Report & Trade Opportunity Analysis Reports - newser.com
Tick level data insight on Lyell Immunopharma Inc. volatilityTrade Analysis Summary & Safe Capital Allocation Plans - newser.com
Is this a good reentry point in Lyell Immunopharma Inc.Recession Risk & Low Risk Entry Point Tips - newser.com
How to manage a losing position in Lyell Immunopharma Inc.July 2025 EndofMonth & Free Low Drawdown Momentum Trade Ideas - newser.com
How to track smart money flows in Lyell Immunopharma Inc.July 2025 Update & Trade Opportunity Analysis - newser.com
Technical signs of recovery in Lyell Immunopharma Inc.2025 Buyback Activity & Weekly Chart Analysis and Guides - newser.com
How institutional ownership impacts Lyell Immunopharma Inc. stock2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
Published on: 2025-10-31 03:26:35 - newser.com
Is it too late to sell Lyell Immunopharma Inc.Portfolio Gains Report & Weekly Stock Performance Updates - newser.com
Is Lyell Immunopharma Inc. still worth holding after the dipWeekly Profit Recap & Precise Swing Trade Entry Alerts - newser.com
Published on: 2025-10-30 06:17:45 - newser.com
Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Thursday - MarketBeat
Published on: 2025-10-30 02:39:25 - newser.com
What hedge fund activity signals for Lyell Immunopharma Inc. stockWeekly Stock Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Published on: 2025-10-28 05:46:43 - newser.com
Lyell Immunopharma Inc Stock Analysis and ForecastTrading Psychology Tips & Achieve Triple Digit Returns - earlytimes.in
Published on: 2025-10-27 19:50:03 - newser.com
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):